Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
nonalcoholic steatohepatitis
affordable care act
biotech
fda
merck
abeona therapeutics
cancer immunotherapy
deals
donald trump
gilead sciences
johnson & johnson
pembrolizumab
What
nash
7
×
roundup
bio
drug
news
disease
american
approved
based
best
biogen’s
companies
continue
crash
debate
fatty
healthcare
industry
kind
known
liver
new
people
pharmaceutical
policy
politicians
pressure
scalps
trump’s
u.s
according
aducanumab
akcea
alzheimer’s
amyloid
angst
approval
bagged
billions
biogen
Language
unset
Current search:
nash
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More